Ionis Pharmaceuticals' stock experienced a significant pre-market plunge of 5.20% on Wednesday, as investors reacted to the company's latest quarterly financial results.

The biopharmaceutical company reported mixed fourth-quarter earnings, with revenue of $203 million beating the Ibes estimate of $156.1 million and adjusted operating income of -$172 million coming in better than the expected -$210.3 million. However, the company's earnings per share forecast showed a loss of $1.32, significantly wider than the prior-year period's loss of $0.66 cents.

Despite beating revenue and operating income estimates, the substantial increase in per-share losses appears to have driven negative investor sentiment during pre-market trading, overshadowing the positive aspects of the earnings report.